All news

Incyte shares climb on trial data and raised 2026 guidance

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Incyte shares rose 4.47% on positive oncology trial data and raised full-year 2026 sales guidance, lifting the stock to a 21.13% year-to-date return. The close of

Read original source

INCY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.